Drugs /

gedatolisib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
gedatolisib
NCI Definition [1]:
An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon intravenous administration, gedatolisib inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.

Clinical Trials

View Clinical Trials for gedatolisib

Gedatolisib has been investigated in 7 clinical trials, of which 5 are open and 2 are closed. Of the trials investigating gedatolisib, 5 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for gedatolisib clinical trials.

Breast carcinoma, adenocarcinoma of the gastroesophageal junction, and bladder carcinoma are the most common diseases being investigated in gedatolisib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Gedatolisib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Gedatolisib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating gedatolisib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pki-587, pf-05212384, dual pi3 kinase/mtor inhibitor pki-587, pf 05212384, urea, n-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-n'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-, 1-(4-[[4-(dimethylamino)piperidin-1-yl]carbonyl]phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, gedatolisib, pki 587, 1-(4-((4-(dimethylamino)piperidin-1-yl)carbonyl)phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea, pki587
Drug Categories [2]:
PI3K inhibitors, Serine/threonine kinase inhibitors, mTORC1/2 catalytic inhibitors
Drug Target(s) [2]:
MTOR, PIK3CA
NCIT ID [1]:
C91732

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.